Vesugen

Overview

Vesugen is a synthetic tripeptide, Lys-Glu-Asp (KED), from the Khavinson short-peptide 'bioregulator' series, positioned as a short-peptide analog of a bovine vascular-tissue polypeptide complex and claimed to be vasoprotective. Marketed on the Russian/Ukrainian grey market; not FDA-approved in the US; research-use only.

Mechanism of Action

Khavinson-group studies propose Vesugen interacts with the promoter region of the MKI67 gene (docking analyses) and restores age-related decline in Ki-67 expression in vascular endothelial cell cultures, implying an epigenetic-regulation mechanism. Mechanistic claims are confined to the Khavinson lab and have not been independently characterized in Western vascular pharmacology.

Research Summary

Evidence base is single-lab (Khavinson/Linkova and collaborators). Preclinical work includes organotypic neuroimmunoendocrine cultures (Bull Exp Biol Med 2012) and endothelial-cell epigenetics studies (Adv Gerontol 2014). No FDA-registered trials; no Western RCTs in vascular disease.

Vendors selling Vesugen

Scored vendors carrying Vesugen, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.

Reported Side Effects

• Injection site irritation
• Rare hypersensitivity

Compare Vesugen with Others

Research References

• Chalisova et al. — Effect of tripeptide Lys-Glu-Asp on physiological activity of neuroimmunoendocrine system cells (Bull Exp Biol Med) (2012)
• Khavinson et al. — Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging (covers Vesugen / Lys-Glu-Asp, Adv Gerontol, Russian) (2014)

Frequently asked questions

Has Vesugen been independently lab-tested?

Disclosed Labs has collected 10 Certificates of Analysis (COA) for Vesugen from 5 independent testing labs. 6 vendors have submitted material for testing. Products average 99.6% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/vesugen/testing.

What is the average purity of Vesugen on the market?

Based on 10 COAs analyzed by Disclosed Labs, Vesugen products average 99.6% (±0.2%) tested purity. Individual vendor results vary; see per-vendor COA data at https://www.disclosedlabs.com/peptides/vesugen/coas.

Where can researchers source Vesugen?

4 vendors with Disclosed Labs trust grades currently list Vesugen, including Peptidology, Peptide Supply Co., BioLongevity Labs. Compare live prices and lab-verified COAs at https://www.disclosedlabs.com/prices/vesugen.

How does Vesugen work?

Khavinson-group studies propose Vesugen interacts with the promoter region of the MKI67 gene (docking analyses) and restores age-related decline in Ki-67 expression in vascular endothelial cell cultures, implying an epigenetic-regulation mechanism. Mechanistic claims are confined to the Khavinson lab and have not been independently characterized in Western vascular pharmacology.

What does the research say about Vesugen?

Evidence base is single-lab (Khavinson/Linkova and collaborators). Preclinical work includes organotypic neuroimmunoendocrine cultures (Bull Exp Biol Med 2012) and endothelial-cell epigenetics studies (Adv Gerontol 2014). No FDA-registered trials; no Western RCTs in vascular disease.